THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM

11/12/2025 - Article updated to correct "Jim Krieg" to "James Kreig"

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism of action.

• Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and manufacturers

• Integration of technology and physical infrastructure positions Wellgistics with the "Pharmacy IT Railroad" to execute on PharmacyChain™ smart contracts for optimized healthcare delivery in the $634 billion United States prescription drug market

With a staggering 1405.46% revenue surge since February 2024, CBDL continues its explosive expansion as Smoking Scholars places another major order in New York's $7.2 billion cannabis market.

The physician-owned practice offers families comprehensive care, allowing patients to receive care for all of their medical needs at one of its 45-plus locations, with over 225 providers.

- Continued low early termination rate among the first 80 study completers suggests Halneuron^® and placebotreatmenthave been well tolerated

The best MTF top surgeon is Dr. Sajan

New cross-functional "Alpha Labs" team will fast-track AI and automation capabilities from concept to product, helping long-term care pharmacies work smarter, faster, and more efficiently.

DOHC strengthens its commitment to mothers and families through expanded education and personalized prenatal support

A very unique multi-vertical health AI engine capable of early detection for mental health, wound infection, skin cancer, and disease risk-all through a smartphone

First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September

Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67^th Annual American Society of Hematology (ASH) meeting in December

First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist

IND-enabling studies progressing as planned with triple-GLP/GIP/GCG agonists PN-477sc and PN-477o

Oral hepcidin development candidate expected to be nominated by year end

Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028

Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric intestinal failure patients ranging between 12% to 37%

Integration boosts Grid AI's deployment capacity as AI data-center power demand approaches 50 GW, growing by over 165% through 2030ⁱ

VSee explores collaboration with Philippine Tuberculosis Society and former VP Leni Robredo to expand digital health innovation for Naga City starting with maternal health and primary care

89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials

Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors

Both molecules leverage Aptevo's unique use of the CRIS-7-derived CD3 binding domain, associated with favorable safety outcomes in the clinic; CD3 T-cell engager portfolio expanded to five

Company raises $18.7 million in the third quarter, $4.1 million since quarter end, extends cash runway into 4Q26

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)

Narrows 2025 projected revenue range to $1.6 - $2.0 billion

Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion

Increases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion

Hundreds gather at Cathedral City Amphitheater Park for a day of wellness, community connection, and preventive health education

Sportstech Revenue Growth Accelerated from 18% YoY in Second Quarter, and is Expected to Surpass 30% YoY in Fourth Quarter

Current FX Rates Indicate that Sportstech's LTM September 2025 Revenue Would Be Approximately $58M with $6M in LTM EBITDA

TRNR Confirms that All Parties Working Diligently on Completing Acquisition Closing Requirements

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan

Addison enables continuous patient oversight, early intervention, and intelligent adherence through customizable RPM/CCM integration.

The Voorhees clinic, located at 1006 Kresson Road near Centennial Blvd, will host a ribbon cutting on November 6 at 2 p.m. in partnership with the Southern New Jersey Chamber of Commerce.

Successful loading of CBD material accelerates the path to revenue.

• Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last year

• U.S. revenue increased 115% for the quarter and 86% for the six months ended September 30, 2025 compared to same periods last year

• Net loss per share decreased 46% for the quarter and 42% for the six months ended September 30, 2025 compared to same periods last year

Volume-based contract with no revenue ceiling covers virtual urgent care and behavioral health across more than 100 facilities; services commence January 1, 2026.

Toy drive with Operation Warm Heart benefits Airmen at Nellis & Creech AFBs; Family fun, food, spirits and beverages made affordable and accessible by the Compassion Center; Sponsors urged to confirm placements as inventory nears capacity

Bringing Next-Generation Wellness to a Global Audience with Multilingual, Accessible AI Solutions

- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody
- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update

• Demonstrated feasibility of effective DNA delivery with Company's xPhore^™ nanoparticle technology

• DNA delivery technology to be offered as GenePhore^™ to biotech / pharma companies

• Addressing large and growing market

Key Highlights:

• Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026 market launch.

• Pivot will be First Two-Part Tubeless Patch Pump: Pivot, a 3 milliliter removable patch pump, targets the $3 billion dollar market for adult "almost-pumpers" with its affordable, user-friendly, easy-to-learn design.

High-Volume Manufacturing Readiness: Modular Medical's scalable platform positions it to target a significant share of the insulin pump market.

HUMAN PERFORMANCE ANGLE